OCT 16, 2013 06:00 AM PDT

Building an Ion AmpliSeq Colon and Lung Cancer Panel - Consortium development of a tool for clinical research applications

  • Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
      Dr. Normanno earned his Medical Doctor Degree in 1988 at the Medical School of the University of Naples (Italy) Federico II. He received his spacialization in Medical Oncology in 1991, and in Hematology in 2001, at the same university. Between 1990 and 1993, Dr. Normanno completed a postoctoral fellowship studying tumor growth factors at the National Institutes of Health, Bethesda, MD. Since 1993, Dr. Normanno's areas of research have been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; and identification of markers of response or resistance to anti EGFR agents. Dr. Normanno is a member of the American Association for Cancer Research, the Italian Tumor Society, and the Italian Cancer Society. He is the author of over 140 papers published in peer reviewed journals. After serving as Senior Investigator, and later, Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same Hospital, and since 2006, is also Director of the Research Department.


    The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of tumors carrying mutations in druggable genes have been identified in CRC and NSCLC. In this respect, the availability of approaches that are compatible with small amounts of input DNA from FFPE tissue and that allow a rapid screening of a large number of somatic mutations is definitely needed. Ion AmpliSeq technology introduces a groundbreaking workflow enabling the rapid sequencing of hundreds of mutations with low allele frequency using as little as 10ng of DNA per reaction. The OncoNetwork Consortium is a European collaborative effort of 8 Cancer Translational Research Institutions to evaluate a custom panel targeting hotspots mutations in 22 genes implicated in CRC and NSCLC. In particular, 7 labs will test the gene panel in 3 phases using 180 retrospective FFPE samples previously tested with orthogonal technologies, and 1 lab will perform confirmatory testing on novel SNPs.

    Show Resources
    Loading Comments...